Vivian E. Riefberg - 29 Mar 2023 Form 4 Insider Report for Signify Health, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
29 Mar 2023, 08:54:48 UTC
Prior SEC filing
23 May 2022
Next SEC filing
07 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Adam McAnaney, as attorney-in-fact for Vivian E. Riefberg

Key filing fact

Vivian E. Riefberg filed Form 4 for Signify Health, Inc. on 29 Mar 2023.

Key facts

  • This page summarizes Vivian E. Riefberg's Form 4 filing for Signify Health, Inc..
  • 5 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 29 Mar 2023, 08:54.

Change

  • Previous filing in this sequence was filed on 23 May 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGFY transaction

Class A Common Stock

Conversion of derivative security

Transaction value
Shares
+24,173
Change %
+66%
Price
Shares after
60,661
Date
29 Mar 2023
Ownership
Direct
Footnotes
F1
SGFY transaction

Class A Common Stock

Disposed to Issuer

Transaction value
Shares
-14,672
Change %
-24%
Price
Shares after
45,989
Date
29 Mar 2023
Ownership
Direct
Footnotes
F2
SGFY transaction

Class B Common Stock

Disposed to Issuer

Transaction value
Shares
-24,173
Change %
-100%
Price
Shares after
0
Date
29 Mar 2023
Ownership
Direct
Footnotes
F3
SGFY transaction

Class A Common Stock

Disposed to Issuer

Transaction value
Shares
-45,989
Change %
-100%
Price
Shares after
0
Date
29 Mar 2023
Ownership
Direct
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGFY transaction Derivative

LLC Units in Cure Aggregator, LLC

Conversion of derivative security

Transaction value
Shares
-24,173
Change %
-100%
Price
Shares after
0
Date
29 Mar 2023
Ownership
Direct
Underlying class
Class A Common Stock
Underlying amount
24,173
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Vivian E. Riefberg is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock.

Footnote F2

Pursuant to the Merger Agreement, each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU"), that was (i) outstanding immediately prior to the effective time of the merger (the "Effective Time") to the extent vested and unsettled and (ii) any Issuer RSU that was outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer (each, a "Cash-Out RSU"), was cancelled and converted into the right to receive an amount in cash equal to (1) to $30.50 (the "Per Share Consideration") multiplied by (2) the number of shares of the Issuer's Class A Common Stock subject to such Cash-Out RSU.

Footnote F3

Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled.

Footnote F4

Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .